Bevacizumab is an antagonist of VEGF that significantly inhibits tumour angiogenesis and tumour progression and has been recognized as a first-line treatment for liver metastases in CRC [20, 21]. The gene discussed is VEGFA; the disease is colorectal carcinoma.